
Selective NNMT (nicotinamide N-methyltransferase) inhibitor — unlocks fat oxidation and improves cellular energy metabolism.
Ranges cited in research literature. Not a usage recommendation. For research use only.
5-Amino-1MQ (5-amino-1-methylquinolinium) is not a peptide: it is a small molecule, a 158-Da quinolinium cation designed at the University of Texas Medical Branch (Stanley Watowich's laboratory) as a selective inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). It is usually supplied as the iodide salt and, unlike the rest of the catalog, is administered orally in the literature.
NNMT consumes nicotinamide and S-adenosylmethionine to produce 1-methylnicotinamide; when overexpressed in adipose tissue it drains precursors of NAD+ and of the methylation cycle. By inhibiting it, 5-Amino-1MQ raises intracellular NAD+ and SAM, which in cultured adipocytes and in mice on a high-fat diet translated into less lipid accumulation, smaller adipocytes and higher energy expenditure (Neelakantan et al., Biochemical Pharmacology 2018). NNMT is also investigated in cancer, liver fibrosis and muscle aging.
All available evidence is preclinical: cells and rodents. There are no published clinical trials in humans on safety or efficacy, and the molecule has no regulatory status as a drug in any country. It is a laboratory reagent with a well-defined molecular target, which makes it useful for studying the NNMT–NAD+ axis, but any extrapolation to humans is unsupported. Renova distributes it strictly for research use.
| Class | Small molecule (non-peptide) · selective NNMT inhibitor |
| Chemical name | 5-amino-1-methylquinolinium (usually as iodide) |
| CAS | 42464-96-0 |
| Target | Nicotinamide N-methyltransferase (NNMT), low-micromolar IC50 |
| Route in the literature | Oral (murine models); not administered subcutaneously |
| Status | Preclinical; no human trials, no regulatory approval |
| Solubility | Soluble in water and DMSO; protect from light |
No. It is a small molecule of the quinolinium family, only 158 Da, with no amino acids. It is in the catalog for its metabolic target (NNMT), not its structure, and it is the only catalog compound administered orally in the literature.
NNMT methylates nicotinamide, spending NAD+ precursors and S-adenosylmethionine in the process. It is overexpressed in adipose tissue in obesity models and in several tumors. Inhibiting it raises intracellular NAD+ and reduces lipid accumulation in adipocytes, according to cell and mouse studies.
No clinical trials have been published. Available data come from cultured adipocytes and from mice on a high-fat diet (University of Texas Medical Branch, 2018). Human safety and efficacy are uncharacterized.
They are two approaches to the same pathway: NAD+ supplies the coenzyme directly, while 5-Amino-1MQ blocks an enzyme that consumes its precursors. The literature studies them separately; there are no studies of the combination.
Related reading: 5-Amino-1MQ: NNMT Inhibitor · NAD+: The Coenzyme of Cellular Energy and Longevity
Informational content based on published scientific literature; it is not a recommendation for use or medical advice. Product strictly for research use (RUO), not suitable for human or veterinary consumption.
Your cart is empty